文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

mCRPC患者不同[225Ac]Ac/[177Lu]Lu-PSMA联合方案疗效与不良事件的系统评估

Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [225Ac]Ac/[177Lu]Lu-PSMA-therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-14

该研究回顾性评估了19例接受不同活度组合[225Ac]Ac/[177Lu]Lu-PSMA-I&T(ALCT)治疗的mCRPC患者,比较两组间PSMA-PET/CT反应(RECIP 1.0)及不良事件。结果显示两组反应与不良事件均无显著差异,但高225Ac活度组部分缓解比例更高(56% vs 40%),口干发生率也更高(56% vs 30%)。

要点

  • 高225Ac活度组(8 MBq/1000 MBq)部分缓解率56%,低活度组(4 MBq/4000 MBq)为40%。
  • 高225Ac活度组口干发生率56%,低活度组30%,但组间比较无统计学差异。
  • 两组实验室及影像参数绝对值或治疗前后差值均无显著差异。

核心结论

  • 两种ALCT方案在反应和不良事件上无显著差异,但较高225Ac活度可能有利于更好结局,代价是口干风险更高。
  • 较低225Ac活度方案在需保护唾液腺功能和生活质量时可能是较好选择,但需更仔细监测血液指标。

研究设计与样本

  • 回顾性评估19例在本部门以同情用药方式接受ALCT治疗的连续mCRPC患者。
  • 按每周期225Ac/177Lu活度分为两组:组1接受4 MBq和4000 MBq,组2接受8 MBq和1000 MBq。
  • 评估基线及2周期后实验室指标(PSA、ALP、LDH、Hb、Lc、Tc、Crea)和[18F]PSMA-1007-PET/CT影像参数(TTV、SUVmax/mean),并记录不良事件。
  • 采用PSMA-PET/CT反应评价标准RECIP 1.0进行反应评估。

主要发现

  • 按RECIP复合分类,组1中4/10(40%)部分缓解,组2中5/9(56%)部分缓解。
  • 组1中4/10(40%)疾病进展,组2中2/9(22%)疾病进展。
  • 2周期ALCT后新发或加重至少1级的不良事件:组1贫血2/10(20%)、组2贫血3/9(33%)。
  • 组1血小板减少1/10(10%);组1白细胞减少4/10(40%)、组2白细胞减少2/9(22%)。
  • 组1体重下降1/10(10%)、组2体重下降2/9(22%);组1口干3/10(30%)、组2口干5/9(56%)。

关键数值与推荐

  • 反应评价采用RECIP 1.0标准。
  • 组1每周期给予4 MBq 225Ac和4000 MBq 177Lu,组2每周期给予8 MBq 225Ac和1000 MBq 177Lu。
  • 组1部分缓解4/10(40%)、疾病进展4/10(40%);组2部分缓解5/9(56%)、疾病进展2/9(22%)。
  • 组1口干3/10(30%),组2口干5/9(56%)。
  • 两组在治疗后实验室或影像参数绝对值及治疗前后差值上均无显著差异。

临床怎么用

  • 在需保护唾液腺功能和生活质量时,可考虑较低225Ac活度的ALCT方案,但需加强血液指标监测。
  • 若追求更好肿瘤结局且可接受较高口干风险,可考虑较高225Ac活度的ALCT方案。
  • ALCT治疗2周期后应结合RECIP 1.0和PSMA-PET/CT参数评估反应。

局限性

  • 样本量小(共19例),组间比较可能效力不足。
  • 为单中心回顾性研究,患者接受同情用药治疗。
  • 原文未报告统计学P值或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 225Ac-Targeted alpha therapy is a potent and promising option for patients with metastatic castration-resistant prostate cancer (mCRPC) and failure of guideline-based therapies and 177Lu-PSMA-radioligand therapy. Unfortunately, side effects associated with TAT can significantly affect quality of life. A combination treatment regimen adding 177Lu and reducing 225Ac activities may mitigate side effects while preserving sufficient anti-tumour efficacy. We therefore evaluated different combinations [225Ac]Ac-/[177Lu]Lu-PSMA-I&T (ALCT) with regard to response and adverse events. METHODS: A total of 19 consecutive patients treated with ALCT on compassionate use basis at our department were evaluated. Patients were divided into two different subgroups, depending on the 225Ac/177Lu-activity administered: group 1 (Gr1) received 4MBq and 4000MBq, group 2 (Gr2) 8 MBq and 1000MBq per therapy cycle, respectively. Laboratory (PSA, ALP, LDH, Hb, Lc, Tc, Crea) and imaging parameters on [18F]PSMA-1007-PET/CTs (TTV, SUVmax/mean) at baseline and after 2 cycles of therapy were evaluated for the total patient population as well as each therapy subgroup and statistically compared. Adverse events (xerostomia, anemia, leukopenia, thrombocytopenia, weight loss) were recorded. Response evaluation criteria in PSMA-PET/CT (RECIP 1.0) was used for response evaluation. RESULTS: According to the RECIP composite classification, 4 of 10 (40%) of patients from Gr1 and 5 of 9 (56%) from Gr2 showed a partial response, while 4/10 (40%) and 2/9 (22%) of patients from Gr1 and 2, respectively, showed progressive disease. After 2 cycles of ALCT the following adverse events newly developed or worsened by at least one grade: anemia in 2/10 (20%) patients from Gr1 and 3/9 (33%) patients from Gr2; thrombocytopenia in 1/10 (10%) patients from Gr1; leukopenia in 4/10 (40%) from Gr1 and 2/9 (22%) from Gr2; weight loss in 1/10 (10%) from Gr1 and 2/9 (22%) from Gr2 and xerostomia in 3/10 (30%) from Gr1 and 5/9 (56%) from Gr2. There was no significant difference between the two groups in respect to absolute values after therapy or pre- and post-therapy difference in any of the laboratory or imaging parameters evaluated. CONCLUSION: Although no significant difference in response or adverse events could be found between the two treatment groups, ALCT with higher 225Ac-activities seems to favor a better outcome, albeit at the cost of a higher risk of xerostomia. ALCT with lower 225Ac activities may be a good choice when conserving salivary gland function and therefore quality of life is of higher concern, but renders more careful monitoring of blood values necessary.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sheikh GT, Siegmund SC, Widjaja L, et al. Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [225Ac]Ac/[177Lu]Lu-PSMA-therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41530551. doi:10.1007/s00259-025-07744-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。